Document is current
Any future updates will be listed below
-
Authors
Naganawa, Mika https://orcid.org/0000-0002-4408-2621
Gallezot, Jean-Dominique
Finnema, Sjoerd J.
Maguire, Ralph Paul
Mercier, Joël
Nabulsi, Nabeel B.
Kervyn, Sophie
Henry, Shannan
Nicolas, Jean-Marie
Huang, Yiyun
Chen, Ming-Kai
Hannestad, Jonas
Klitgaard, Henrik
Stockis, Armel
Carson, Richard E.
-
Funding
Funding for this research was provided by:
UCB Pharma
- License Information
-
More Information
Article History
Received: 10 August 2022
Accepted: 24 October 2022
First Online: 8 November 2022
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the Yale University Human Investigation Committee and the Yale-New Haven Hospital Radiation Safety Committee. Written informed consent was obtained from all subjects.
: Not applicable.
: M.N., J.-D. G., N.B.N., S.H., Y.H., and M.-K. C. have no conflicts of interest to report. S.J.F. is currently a full-time employee and shareholder of AbbVie. R.P.M., J.M., S.K., J.-M.N., H.K., and A.S. are current employees of UCB Pharma. J.H. was employee of UCB Pharma at the time this work was conducted and is currently a full-time employee of Tranquis Therapeutics, Inc. R.E.C. has received research support from Astellas Pharma, Astra-Zeneca, Bristol Myers Squibb, Lilly, Pfizer, Taisho Pharmaceutical, and UCB Pharma, outside of the submitted work.
